Management of newly treated diabetes in Medicare beneficiaries with and without heart failure

Clinical Cardiology

Volumn 40, Issue 1, 2017, Pages 38-45

  Cooper, Lauren B ^a,b   Mi, Xiaojuan ^c   Mentz, Robert J ^b,c   Green, Jennifer B ^b,c   Anstrom, Kevin J ^b,c   Hernandez, Adrian F ^b,c   Curtis, Lesley H ^b,c  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

cardiac transplantation; cardiomyopathy; Heart failure; myocarditis

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; LOOP DIURETIC AGENT; METFORMIN; MINERALOCORTICOID ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TASPOGLUTIDE; ANTIDIABETIC AGENT;

AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; HEART FAILURE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FOLLOW UP; MULTICENTER STUDY; RETROSPECTIVE STUDY; TIME FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE; METFORMIN; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84995755355     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22603     Document Type: Article

References (25)

1. Standards of medical care in diabetes—2015: summary of revisions. Diabetes Care. 2015;38(suppl):S4.
2. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(suppl 1):S14–S80.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care. 2012;36:490]. Diabetes Care. 2012;35:1364–1379.
5. Eapen ZJ, Hammill BG, Setoguchi S, et al. Who enrolls in the Medicare Part D prescription drug benefit program? Medication use among patients with heart failure. J Am Heart Assoc. 2013;2:e000242.
6. Piccini JP, Mi X, DeWald TA, et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012;9:1403–1408.
7. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43:480–485.
8. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
9. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–590.
10. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol. 2007;49:1696–1704.
11. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26:2983–2989.
12. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30:2148–2153.
13. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–2135.
14. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circ Heart Fail. 2013;6:395–402.
15. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2015. http://packageinserts.bms.com/pi/pi_glucophage_xr.pdf. Accessed August 18, 2016.
16. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2014. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandia/pdf/AVANDIA-PI-MG.PDF. Accessed August 18, 2016.
17. Actos [package insert]. Deerfield, IL: Takeda Pharmaceutical America, Inc., 2011. http://general.takedapharm.com/content/file.aspx?filetypecode=actospi&cacheRandomizer=dcd4900e-c015-4c18-867b-d3a0080be477. Accessed August 18, 2016.
18. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81–85.
19. Vaur L, Gueret P, Lievre M, et al; DIABHYCAR Study Group. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 Diabetes, Hypertension, Cardiovascular Events and Ramipril) study [published correction appears in Diabetes Care. 2003;26:2489]. Diabetes Care. 2003;26:855–860.
20. Romero SP, Andrey JL, Garcia-Egido A, et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus: a propensity-matched study in the community. Int J Cardiol. 2013;166:404–412.
21. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4:53–58.
22. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–2351.
23. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699–703.
24. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD: US Department of Health and Human Services; December 2008.
25. McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843–851.